Newtown biopharm firm could reap $50M from Chinese licensing deal
May 13, 2019 at 12:52 PM EDT
The licensing deal for rigosertib in Greater China includes $6 million upfront in the form of $2 million cash, the purchase of $2 million in Onconova stock and the placement of $2 million in escrow for clinical development expenses.
